BioLife Q2 Revenue Jumps 21% to $28.5M, Operating Income Swings to Profit
BLFS sits 90% above its 52-week low of $17.86.
Summary
BioLife Solutions delivered a strong Q2 with revenue up 21% YoY to $28.5 million, driven by its dominant biopreservation media franchise. GAAP operating income swung to a $1.7 million profit from a $16.1 million loss a year ago, while adjusted EBITDA hit $7.4 million — a 26% margin. The company's media is now embedded in 18 commercial cell and gene therapies and holds over 70% market share in U.S. clinical trials. This performance reinforces the rationale behind Repligen's $1.5 billion acquisition announced in July, which is expected to close in Q4 2026. The 10-Q discloses merger consideration of $11.25 cash plus 0.1442 Repligen shares per BioLife share, and Q2 net income of $45.1 million including a $42.4 million tax benefit. The results show accelerating profitability and market penetration ahead of the merger.
Updated with an SEC 10-Q filing · What changed
Updates
· SEC 10-Q — The 10-Q discloses merger consideration of $11.25 cash plus 0.1442 Repligen shares per BioLife share, and Q2 net income of $45.1M including a $42.4M tax benefit.
At the time of this announcement, BLFS was trading at $33.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $17.86 to $34.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.